Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.

BACKGROUND: Saracatinib (AZD0530), a potent Src inhibitor, is a subject of current evaluation as an anticancer therapy. Increased plasma creatinine levels have previously been observed after saracatinib administration in healthy subjects and this study was undertaken to characterize the underlying mechanism of this increase. SUBJECTS AND METHODS: 56 healthy male subjects were assigned to either single- (n=28; randomised to placebo or saracatinib 500 mg) or multiple-dose oral treatment (n=28; randomised to placebo or saracatinib 125 mg for 14 days). Renal function variables assessed included inulin clearance and tubular secretion of creatinine.
RESULTS: Saracatinib led to a reduction in mean creatinine fractional excretion ratio, which was due to a reduction in tubular secretion of creatinine. Increased plasma creatinine was not associated with decreased glomerular filtration rate or increased creatinine production.
CONCLUSION: The observed increase in plasma creatinine after saracatinib administration was due to reduced tubular secretion of creatinine, but was not considered to be clinically relevant in the context of this study.

RCT Entities:   Population Interventions Outcomes